New vitamin D trials have 'little chance' of showing health benefits, warns analysis

By Nathan Gray

- Last updated on GMT

New vitamin D trials have 'little chance' of showing health benefits, warns analysis
Randomised controlled trials on supplementation with vitamin D seem to show that the vitamin has little causal effect on our health outcomes, according to a new meta-analysis which suggests that future research is 'unlikely' to alter such conclusions.

The study, published in The Lancet Diabetes & Endocrinology​, examined the existing evidence from 40 randomised controlled trials - concluding that vitamin D supplementation does not prevent heart attack, stroke, cancer, or bone fractures in the general population by more than 15%.

Led by Dr Mark Bolland from the University of Auckland, New Zealand, the team behind the new analysis added that as a result vitamin D supplements probably provide little, if any, health benefit - and that future randomised trials with similar designs are 'unlikely' to reveal conclusions any different to those already published.

"Findings from observational studies have shown vitamin D insufficiency to be associated with a wide variety of disorders such as fractures, ischaemic heart disease, cerebrovascular disease, and cancer,"​ noted Bolland and his team. "Such findings have led to calls for widespread vitamin D supplementation. However, some researchers have suggested that such recommendations should not be made without supportive trial data, and they have therefore called for randomised controlled trials of vitamin D supplementation with non-skeletal endpoints as primary outcomes."

Bolland and his colleagues used this trial data to perform several types of meta-analysis including a 'futility analysis', which predicts the potential of future study results to sway existing evidence - the results of which indicate that the effect of vitamin D, taken with or without calcium, on heart attack, stroke, cancer, and total fracture lies below a 'futility threshold'. 

"In view of our findings, there is little justification for prescribing vitamin D supplements to prevent myocardial infarction or ischaemic heart disease, stroke or cerebrovascular disease, cancer, or fractures, or to reduce the risk of death in unselected community-dwelling individuals. Investigators and funding bodies should consider the probable futility of undertaking similar trials of vitamin D to investigate any of these endpoints,"​ said the team.

Related news

Show more

Related products

show more

Your Product Innovation Begins Here: Booth 4055

Your Product Innovation Begins Here: Booth 4055

Content provided by Effepharm Ltd | 22-Oct-2024 | Product Brochure

EffePharm will showcase innovative anti-aging solutions, featuring UthPeak™, world’s first self-GRAS approved NMNH, which boosts NAD+ levels by 10X. UthPeak™...

LocVita® Natural Vitamin E Acetate 950IU Beadlets

LocVita® Natural Vitamin E Acetate 950IU Beadlets

Content provided by INNOBIO Corporation Limited | 20-Sep-2024 | White Paper

Incorporating double-layer encapsulation technology, LocVita® Natural Vitamin E Acetate 950IU Beadlets demonstrate improved stability and pressure resistance.

Your guide to nutritional care innovation

Your guide to nutritional care innovation

Content provided by dsm-firmenich | 20-Aug-2024 | Insight Guide

The medical nutrition market is primed for innovation due to aging populations, chronic diseases, nutrition awareness and scientific advances. Our comprehensive...

Related suppliers

Follow us

Products

View more

Webinars